BioMarin Pharmaceuticals
BMRN
467 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 181 increasing their positions, 133 reducing their positions, and 45 closing their positions.
80% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 45
36% more repeat investments, than reductions
Existing positions increased: 181 | Existing positions reduced: 133
25% more capital invested
Capital invested by funds: $11.7B → $14.7B (+$2.94B)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
7% more funds holding
Funds holding: 436 → 467 (+31)
6% more call options, than puts
Call options by funds: $156M | Put options by funds: $147M
0.32% less ownership
Funds ownership: 96.93% → 96.62% (-0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$332M |
| 2 |
JP Morgan Chase
New York
|
+$98.3M |
| 3 |
Primecap Management
Pasadena,
California
|
+$88.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$39.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$36.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$375M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$123M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$121M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$108M |
| 5 |
Jennison Associates
New York
|
-$97.5M |
BMRN Hedge Fund Activity: Q4 2019 in Review
467 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2019, worth a combined $14.7B — up 25% from $11.7B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new BMRN positions and 45 closed out — a net gain of 36 holders — while 181 added to existing stakes and 133 trimmed.
The largest buyer was Dodge & Cox, opening a new position worth an estimated $332M. The largest seller was Sands Capital Management, exiting entirely with an estimated $375M sold.
- 467 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2019, up from 436 in Q3 2019.
- Funds reported $14.7B of BioMarin Pharmaceuticals stock for Q4 2019, up 25% quarter-over-quarter.
- 81 funds opened new BioMarin Pharmaceuticals positions in Q4 2019 and 45 closed out, a net change of +36 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2019 was Dodge & Cox, an estimated $332M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2019 was Sands Capital Management, an estimated $375M sold.
Based on aggregated 13F filings for Q4 2019.